BACKGROUND: Routine Human Immunodeficiency Virus (HIV) testing, called provider-initiated opt-out HIV testing and counseling (PITC), is recommended in African countries with high HIV prevalence. However, it is unknown whether PITC increases access to pediatric HIV care. In 2008, the Baylor International Pediatric AIDS Initiative implemented PITC (BIPAI-PITC) at a Malawian hospital. We sought to evaluate the influence of BIPAI-PITC, compared with nonroutine HIV testing (NRT), on pediatric HIV care access. METHODS: Retrospective data from 7077 pediatric inpatients were collected during sequential 4-month periods of NRT and BIPAI-PITC. In-hospital and 1-year outcomes for 337 HIV-infected and HIV-exposed uninfected inpatients not previously enrolled in HIV care were analyzed to assess the clinical influence of each testing strategy. RESULTS: During BIPAI-PITC, a greater proportion of all hospitalized children received HIV testing (81.0% vs. 33.3%, P < 0.001), accessed inpatient HIV-trained care (7.5% vs. 2.4%, P < 0.001), enrolled into an outpatient HIV clinic after discharge (3.2% vs. 1.3%, P < 0.001), and initiated antiretroviral therapy (ART) after hospitalization (1.1% vs. 0.6%, P = 0.010) compared with NRT. Additionally, BIPAI-PITC increased the proportion of hospitalized HIV-infected and HIV-exposed uninfected children receiving DNA polymerase chain reaction testing (73.5% vs. 35.2%, P < 0.001), but did not improve outpatient enrollment or ART initiation of identified HIV-infected patients. CONCLUSIONS: BIPAI-PITC increases access to inpatient and outpatient pediatric HIV care for hospitalized children, including DNA polymerase chain reaction testing and ART. Broader implementation of BIPAI-PITC or similar approaches, along with more pediatric HIV-trained clinicians and improved defaulter-tracking methods, would improve pediatric HIV service utilization globally.
BACKGROUND: Routine Human Immunodeficiency Virus (HIV) testing, called provider-initiated opt-out HIV testing and counseling (PITC), is recommended in African countries with high HIV prevalence. However, it is unknown whether PITC increases access to pediatric HIV care. In 2008, the Baylor International Pediatric AIDS Initiative implemented PITC (BIPAI-PITC) at a Malawian hospital. We sought to evaluate the influence of BIPAI-PITC, compared with nonroutine HIV testing (NRT), on pediatric HIV care access. METHODS: Retrospective data from 7077 pediatric inpatients were collected during sequential 4-month periods of NRT and BIPAI-PITC. In-hospital and 1-year outcomes for 337 HIV-infected and HIV-exposed uninfected inpatients not previously enrolled in HIV care were analyzed to assess the clinical influence of each testing strategy. RESULTS: During BIPAI-PITC, a greater proportion of all hospitalized children received HIV testing (81.0% vs. 33.3%, P < 0.001), accessed inpatient HIV-trained care (7.5% vs. 2.4%, P < 0.001), enrolled into an outpatientHIV clinic after discharge (3.2% vs. 1.3%, P < 0.001), and initiated antiretroviral therapy (ART) after hospitalization (1.1% vs. 0.6%, P = 0.010) compared with NRT. Additionally, BIPAI-PITC increased the proportion of hospitalized HIV-infected and HIV-exposed uninfected children receiving DNA polymerase chain reaction testing (73.5% vs. 35.2%, P < 0.001), but did not improve outpatient enrollment or ART initiation of identified HIV-infectedpatients. CONCLUSIONS: BIPAI-PITC increases access to inpatient and outpatient pediatric HIV care for hospitalized children, including DNA polymerase chain reaction testing and ART. Broader implementation of BIPAI-PITC or similar approaches, along with more pediatric HIV-trained clinicians and improved defaulter-tracking methods, would improve pediatric HIV service utilization globally.
Authors: Geert Tom Heikens; James Bunn; Beatrice Amadi; Mark Manary; Meera Chhagan; James A Berkley; Nigel Rollins; Paul Kelly; Charlotte Adamczick; Kathryn Maitland; Andrew Tomkins Journal: Lancet Date: 2008-04-12 Impact factor: 79.321
Authors: Newton I Kumwenda; Donald R Hoover; Lynne M Mofenson; Michael C Thigpen; George Kafulafula; Qing Li; Linda Mipando; Kondwani Nkanaunena; Tsedal Mebrahtu; Marc Bulterys; Mary Glenn Fowler; Taha E Taha Journal: N Engl J Med Date: 2008-06-04 Impact factor: 91.245
Authors: Avy Violari; Mark F Cotton; Diana M Gibb; Abdel G Babiker; Jan Steyn; Shabir A Madhi; Patrick Jean-Philippe; James A McIntyre Journal: N Engl J Med Date: 2008-11-20 Impact factor: 91.245
Authors: Anjuli D Wagner; Cyrus Mugo; Irene N Njuguna; Elizabeth Maleche-Obimbo; Kenneth Sherr; Irene W Inwani; James P Hughes; Dalton C Wamalwa; Grace C John-Stewart; Jennifer A Slyker Journal: J Acquir Immune Defic Syndr Date: 2016-12-15 Impact factor: 3.731
Authors: Eric D McCollum; Geoffrey A Preidis; Madalitso Maliwichi; Dan Olson; L Madeline McCrary; Peter N Kazembe; Charles van der Horst; Irving Hoffman; Mina C Hosseinipour Journal: J Acquir Immune Defic Syndr Date: 2014-05-01 Impact factor: 3.731
Authors: Eric D McCollum; Erica Bjornstad; Geoffrey A Preidis; Mina C Hosseinipour; Norman Lufesi Journal: Trans R Soc Trop Med Hyg Date: 2013-05 Impact factor: 2.184
Authors: Saeed Ahmed; Maria H Kim; Nandita Sugandhi; B Ryan Phelps; Rachael Sabelli; Mamadou O Diallo; Paul Young; Dana Duncan; Scott E Kellerman Journal: AIDS Date: 2013-11 Impact factor: 4.177
Authors: Daniel Olson; Geoffrey A Preidis; Robert Milazi; Jennifer K Spinler; Norman Lufesi; Charles Mwansambo; Mina C Hosseinipour; Eric D McCollum Journal: Trop Med Int Health Date: 2013-04-22 Impact factor: 2.622
Authors: Nicollate Okoko; Jayne L Kulzer; Kristen Ohe; Margaret Mburu; Hellen Muttai; Lisa L Abuogi; Elizabeth A Bukusi; Craig R Cohen; Jeremy Penner Journal: Int J STD AIDS Date: 2020-07-21 Impact factor: 1.359
Authors: Geoffrey A Preidis; Eric D McCollum; William Kamiyango; Alejandro Garbino; Mina C Hosseinipour; Peter N Kazembe; Gordon E Schutze; Mark W Kline Journal: J Acquir Immune Defic Syndr Date: 2013-05-01 Impact factor: 3.731